Substance / Medication

Nintedanib

Overview

Active Ingredient
nintedanib
RxNorm CUI
1592737

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
1
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases.
Hartmann Sonja, Janssen Julie, Ribbing Jakob et al. · CPT Pharmacometrics Syst Pharmacol · 2026
PMID: 41268834Meta-AnalysisFull text (PMC)
The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.
Al Oweidat Khaled S, Abdulelah Ahmed A, Toubasi Ahmad A et al. · Can Respir J · 2025
PMID: 40630797Meta-AnalysisFull text (PMC)
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati Francesco, Stainer Anna, Polelli Veronica et al. · Int J Mol Sci · 2023
PMID: 37175556Meta-AnalysisFull text (PMC)
Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura Marya, Mammen Manoj J, Herman Derrick D et al. · Ann Am Thorac Soc · 2022
PMID: 35499854Meta-Analysis
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Bonella Francesco, Cottin Vincent, Valenzuela Claudia et al. · Adv Ther · 2022
PMID: 35576048Meta-AnalysisFull text (PMC)
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino Enrica, Provenzani Alessio, Vitulo Patrizio et al. · Ann Pharmacother · 2021
PMID: 33054319Meta-Analysis
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Barra Fabio, Laganà Antonio Simone, Ghezzi Fabio et al. · Gynecol Obstet Invest · 2019
PMID: 30304728Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nintedanib (substance)
SNOMED CT
712494002
UMLS CUI
C2930789
RxNorm CUI
1592737

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.